Compare CLWT & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | VIVS |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | 13 |
| Industry | Professional and commerical equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 5.0M |
| IPO Year | 1996 | N/A |
| Metric | CLWT | VIVS |
|---|---|---|
| Price | $1.22 | $2.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 211.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.42 |
| 52 Week High | $1.63 | $5.30 |
| Indicator | CLWT | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 49.52 |
| Support Level | $1.20 | $1.75 |
| Resistance Level | $1.30 | $2.17 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 75.00 | 55.51 |
Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.